Selasa, 24 Mei 2011

FDA For Beckman Coulter's Synchron Flow Cell with Class I Recall-Serious

Earlier this year the company was bought by Danaher for just under $6 billion and this is not good news right now.  The FDA recall page for the models and devices affected can be found here.   The item is not a consumer concern as it is one found more commonly in hospitals and labs. 

“These systems are computer-controlled clinical chemistry analyzers used to determine different types of blood chemistries and other chemistries from blood samples collected from an individual. Analyses are performed on a variety of fluids including blood, urine, and cerebrospinal fluid.”

Danaher Pays $5.87 Billion to Acquire Beckman Coulter Headquartered in Brea, CA

image

Last year before the buyout the company had issues even with their employer health insurance plan as United began switching over from the old Pacificare polities to new United equivalents and one hospital in particular wouldn’t honor the old contracts.  BD

Employers in Orange County Looking for New HMO Contracts as St. Josephs and Some Others Begin Cancelling Agreements with Pacificare (UnitedHeatlhCare) – Employer Capitation Contracts

The FDA put a Class I recall on Beckman Coulter Inc.'s (NYSE:BEC) Synchron clinical chemistry analyzer.

The device is a computer-controlled clinical analyzer for determining chemistries in various fluids including blood, urine and cerebrospinal fluid.

Recall: FDA hits Beckman Coulter's Synchron flow cell with Class I recall | MassDevice - Medical Device Industry News

Tidak ada komentar:

Posting Komentar